We are live on ! Find out more
GILD icon

Gilead Sciences

1,528 hedge funds and large institutions have $79.3B invested in Gilead Sciences in 2018 Q3 according to their latest regulatory filings, with 91 funds opening new positions, 539 increasing their positions, 693 reducing their positions, and 72 closing their positions.

New
Increased
Maintained
Reduced
Closed

26% more first-time investments, than exits

New positions opened: 91 | Existing positions closed: 72

21% more funds holding in top 10

Funds holding in top 10: 4757 (+10)

9% more capital invested

Capital invested by funds: $72.7B → $79.3B (+$6.6B)

0% more funds holding

Funds holding: 1,5231,528 (+5)

0.31% more ownership

Funds ownership: 79%79.31% (+0.31%)

22% less repeat investments, than reductions

Existing positions increased: 539 | Existing positions reduced: 693

27% less call options, than puts

Call options by funds: $1.21B | Put options by funds: $1.66B

Holders
1,528
Holders Change
+5
Holders Change %
+0.33%
% of All Funds
34.93%
Holding in Top 10
57
Holding in Top 10 Change
+10
Holding in Top 10 Change %
+21.28%
% of All Funds
1.3%
New
91
Increased
539
Reduced
693
Closed
72
Calls
$1.21B
Puts
$1.66B
Net Calls
-$449M
Net Calls Change
+$117M
Name Holding Trade Value Shares
Change
Change in
Stake
V
626
Veritable
Delaware
$3.22M -$60.7K -804 -2%
AAIM
627
American Assets Investment Management
California
$3.22M
PCIA
628
Prime Capital Investment Advisors
Kansas
$3.21M +$900K +11,915 +40%
CAMG
629
CWA Asset Management Group
Florida
$3.18M +$232K +3,070 +8%
EWM
630
Evercore Wealth Management
New York
$3.16M -$27.6K -365 -0.9%
VST
631
Van Strum & Towne
California
$3.15M
NRS
632
Neville Rodie & Shaw
New York
$3.15M -$21.1K -279 -0.7%
LWCFA
633
Loring Wolcott & Coolidge Fiduciary Advisors
Massachusetts
$3.14M -$10.8M -143,526 -78%
Walleye Trading
634
Walleye Trading
New York
$3.13M -$1.63M -21,558 -35%
SAM
635
Silvercrest Asset Management
New York
$3.1M -$123K -1,623 -4%
CBB
636
Citizens Business Bank
California
$3.08M -$408K -5,400 -12%
SGA
637
Strategic Global Advisors
California
$3.08M -$9.59K -127 -0.3%
MYLI
638
Meiji Yasuda Life Insurance
Japan
$3.06M +$699K +9,250 +30%
AI
639
Atria Investments
North Carolina
$3.05M -$493K -6,526 -14%
PCM
640
Poehling Capital Management
Wisconsin
$3.02M +$773K +10,230 +35%
SWP
641
Stratos Wealth Partners
Ohio
$3.01M +$71.4K +946 +2%
LNWWM
642
Laird Norton Wetherby Wealth Management
California
$2.99M -$7.17K -95 -0.2%
HT
643
HAP Trading
New York
$2.97M +$2.91M +38,520 New
CG
644
Cutler Group
California
$2.97M +$17.8K +236 +0.6%
AIA
645
AIMZ Investment Advisors
California
$2.96M +$18.7K +248 +0.6%
HCMT
646
Highland Capital Management (Tennessee)
Tennessee
$2.96M -$30K -397 -1%
ACM
647
Azimuth Capital Management
Michigan
$2.96M +$37.8K +500 +1%
NCM
648
Narwhal Capital Management
Georgia
$2.95M +$355K +4,695 +14%
SSB
649
Sandy Spring Bank
Maryland
$2.95M -$98.6K -1,305 -3%
SIRP
650
Shelter Insurance Retirement Plan
Missouri
$2.94M

GILD Hedge Fund Activity: Q3 2018 in Review

1,528 of the 4,375 institutional investors tracked by Wall St. Rank reported a position in Gilead Sciences (GILD) for Q3 2018, worth a combined $79.3B — up 9.1% from $72.7B a quarter earlier.

Buyers outnumbered sellers: 91 funds opened new GILD positions and 72 closed out — a net gain of 19 holders — while 539 added to existing stakes and 693 trimmed.

The largest buyer was Capital Research Global Investors, adding an estimated $968M. The largest seller was Parnassus Investments, cutting an estimated $683M.

  • 1,528 institutional investors held Gilead Sciences (GILD) as of Q3 2018, up from 1,523 in Q2 2018.
  • Funds reported $79.3B of Gilead Sciences stock for Q3 2018, up 9.1% quarter-over-quarter.
  • 91 funds opened new Gilead Sciences positions in Q3 2018 and 72 closed out, a net change of +19 holders.
  • The largest Gilead Sciences buyer in Q3 2018 was Capital Research Global Investors, an estimated $968M added.
  • The largest Gilead Sciences seller in Q3 2018 was Parnassus Investments, an estimated $683M sold.

Based on aggregated 13F filings for Q3 2018.